Maturity Onset Diabetes of the Young Clinical Trials

Find Maturity Onset Diabetes of the Young Clinical Trials Near You

Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial

Who is this study for? Patients with type 2 diabetes
What treatments are being studied? Taurine
Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 80
Healthy Volunteers: f
View:

• Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;

• Age over 30 years;

• BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;

• HbA1c between 7.5% and 10.5%.

Locations
Other Locations
Brazil
Hospital de Clínicas
RECRUITING
Porto Alegre
Contact Information
Primary
Beatriz D Schaan, PhD
bschaan@hcpa.edu.br
55 51 3359-8000
Backup
Rosane Gomez, PhD
rogomez@hcpa.edu.br
55 51 33082823
Time Frame
Start Date: 2021-06-12
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 94
Treatments
Placebo_comparator: Placebo
Participants into the placebo group will receive the same treatment regimen, but with packets of the same appearance and size containing only vehicle.
Active_comparator: Taurine
Participants will receive 6 gy taurine divided into twice/day orally administration for 12 weeks.
Sponsors
Leads: Hospital de Clinicas de Porto Alegre

This content was sourced from clinicaltrials.gov